MedTrace Logo

A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia

NCT01651273 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2013-08-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of BMS-852927 after 28 days of dosing in patients with high cholesterol.

Conditions

Interventions

DRUG

BMS-852927

Capsules, Oral, 0.25 mg, Once daily, 28 days

DRUG

BMS-852927

Capsules, Oral, 1.0 mg, Once daily, 28 days

DRUG

BMS-852927

Capsules, Oral, 2.5 mg, Once daily, 28 days

DRUG

Placebo

Capsules, Oral, 0 mg, Once daily, 28 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Canada
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01651273 on ClinicalTrials.gov